Application of G-CSF in Congestive Heart Failure Treatment

Author(s): Atena Pourtaji, Vajiheh Jahani, Seyed Mohammad Hassan Moallem, Asieh karimani, Amir Hooshang Mohammadpour*.

Journal Name: Current Cardiology Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Introduction: Congestive Heart Failure (CHF) is a disorder in which the heart is unable to supply enough blood for body tissues. Since heart is an adaptable organ, it overcomes this condition by going under remodeling process. Considering cardiac myocytes are capable of proliferation after MI, stimulation of neovascularization as well as their regeneration might serve as a novel target in cardiac remodeling prevention and CHF treatment. Granulocyte Colony-Stimulating Factor (G-CSF), is a hematopoietic cytokine that promotes proliferation and differentiation of neutrophils and is involved in cardiac repair after MI. So far, this is the first review to focus on GCSF as a novel treatment for heart failure.

Methods: We conducted a search of some databases such as PubMed for articles and reviews published between 2003 and 2017, with different keywords including “G-CSF”, “congestive heart failure”, “new therapies for CHF”, “filgrastim”, “in vivo study”.

Results: GCSF exerts its beneficial effects on cardiac repair through either stem cell mobilization or direct angiogenesis promotion. All of which are capable of promoting cardiac cell repair.

Conclusion: GCSF is a promising target in CHF-therapy by means of cardiac repair and remodeling prevention through multiple mechanisms, which are effective enough to be used in clinical practice.

Keywords: In vivo study, new therapies for CHF, filgrastim, congestive heart failure, G-CSF, prevention.

[1]
Liu T, Song D, Dong J, et al. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol 2017; 8: 238.
[2]
Lucas C, van Pol P, Smeets JE, Niesing M, Verwey H, Beeres S. Heart failure in 2015: Let’s get organised! Netherlands Heart J 2015; 23(9): 447-9.
[3]
van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016; 18(3): 242-52.
[4]
Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: Preventing disease and death worldwide. ESC Heart Fail 2014; 1(1): 4-25.
[5]
Milberg P, Klocke R, Frommeyer G, et al. G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis, angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure. Basic Res Cardiol 2011; 106(6): 995-1008.
[6]
Alexander RW, Schlant RC, Fuster V. Hurst’s the heart, arteries and veins. McGraw-Hill, Health Professions Division 1998.
[7]
Takano H, Qin Y, Hasegawa H, et al. Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction. J Mol Med 2006; 84(3): 185-93.
[8]
Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98(18): 10344-9.
[9]
Nagai T, Komuro I. Gene and cytokine therapy for heart failure: Molecular mechanisms in the improvement of cardiac function. Am J Physiol Heart Circ Physiol 2012; 303(5): H501-12.
[10]
Kurdi M, Booz GW. G‐CSF‐based stem cell therapy for the heart—unresolved issues part A: Paracrine actions, mobilization, and delivery. Congest Heart Fail 2007; 13(4): 221-7.
[11]
Fujita J, Mori M, Kawada H, et al. Administration of granulocyte colony‐stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell‐derived myofibroblasts and contributes to cardiac repair. Stem Cells 2007; 25(11): 2750-9.
[12]
Ping P, Anzai T, Gao M, Hammond H. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol Heart Circ Physiol 1997; 273(2): H707-17.
[13]
Hasegawa H, Takano H, Iwanaga K, et al. Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol 2006; 47(4): 842-9.
[14]
Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001; 107(8): 967.
[15]
Daltro PS, Alves PS, Castro MF, et al. Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. BMC Cardiovasc Disord 2015; 15(1): 162.
[16]
Li Y, Takemura G, Okada H, et al. Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. Lab Invest 2006; 86(1): 32.
[17]
Hiraumi Y, Iwai-Kanai E, Baba S, et al. Granulocyte colony-stimulating factor protects cardiac mitochondria in the early phase of cardiac injury. Am J Physiol Heart Circ Physiol 2009; 296(3): H823-32.
[18]
Nieto-Lima B, Cano-Martinez A, Zarco-Olvera G, Masso-Rojas F, Paez-Arenas A, Guarner-Lans V. GCSF partially repairs heart damage induced by repetitive beta-adrenergic stimulation in mice: Potential role of the mobilized bone marrow-derived cells. Int J Pharmacol 2016; 12(7): 689-700.
[19]
Hashemzaei M, Imen Shahidi M, Moallem SA, Abnous K, Ghorbani M, Mohamadpour AH. Modulation of JAK2, STAT3 and Akt1 proteins by granulocyte colony stimulating factor following carbon monoxide poisoning in male rat. Drug Chem Toxicol 2016; 39(4): 375-9.
[20]
Wolk MJ, Scheidt S, Killip T. Heart failure complicating acute myocardial infarction. Circulation 1972; 45(5): 1125-38.
[21]
Joseph J, Rimawi A, Mehta P, et al. Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. Am J Cardiol 2006; 97(5): 681-4.
[22]
Leone AM, Giannico MB, Bruno I, et al. Safety and efficacy of G-CSF in patients with ischemic heart failure: The CORNER (Cell Option for Recovery in the Non-Eligible patients for Revascularization) study. Int J Cardiol 2011; 150(1): 75-8.
[23]
Wenger NK. Quality of life: Can it and should it be assessed in patients with heart failure? Cardiology 1989; 76(5): 391-8.
[24]
Rana JS, Mannam A, Donnell-Fink L, Gervino EV, Sellke FW, Laham RJ. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 2005; 95(12): 1456-9.
[25]
Hüttmann A, Dührsen U, Stypmann J, et al. Granulocyte colony–stimulating factor–induced blood stem cell mobilisation in patients with chronic heart failure. Basic Res Cardiol 2006; 101(1): 78-86.
[26]
Matsubara H. Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy. Lancet 2004; 363(9411): 746-7.
[27]
Hamshere S, Arnous S, Choudhury T, et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: The REGENERATE-DCM clinical trial. Eur Heart J 2015; 36(44): 3061-9.
[28]
Kastrup J. Revival of cytokine therapy in heart failure? Eur Heart J 2015; 36(44): 3070-3.
[29]
Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013; 128(11)(Suppl. 1): S42-9.
[30]
Lezaic L, Socan A, Poglajen G, et al. Intracoronary transplantation of CD34+ cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J Card Fail 2015; 21(2): 145-52.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [83 - 90]
Pages: 8
DOI: 10.2174/1573403X14666181031115118
Price: $58

Article Metrics

PDF: 29
HTML: 2
EPUB: 1
PRC: 1